Lonza Group Ltd (LONN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Thibault ...

Lonza’s biologics segment accounted for 51% of its ... Due to the high switching costs, Lonza manufactures products for the entirety of their commercial life, which is often around 10 years.

We think Lonza is well positioned to deliver strong performance, particularly in the fast-growing biologics and cell ... We sell different types of products and services to both investment ...

KeyBanc Capital Markets increased its price target for Lonza Group (LONN:SW) (OTC: LZAGY) shares to CHF 635 from CHF 610, ...

The biologics drug substance manufacturing market is witnessing substantial expansion, largely due to the growing prevalence of chronic diseases, which is driving the need for biologics development ...

including Lonza, Thermo Fisher and Catalent. But Korean powerhouse Samsung Biologics has somehow avoided the slide. The company has reported another robust increase in its top line, with a 23% ...

Global Cell-Based Assays Market size is expected to be worth around US$ 37.1 Billion by 2032 from US$ 17.7 Billion in 2023, growing at a CAGR of 8.8% ...